SCTbio vs Takeda: CDMO Comparison
How does SCTbio compare to Takeda for Cell Therapy manufacturing?
Side-by-side comparison of SCTbio and Takeda on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Takeda has more FDA inspections on record (4 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Takeda has materially broader EMA GMP coverage (18 active certificates vs 5) — stronger EU footprint.
- Takeda appears as a manufacturing partner on more matched clinical programs (100 vs 0) — a broader sponsor book.
On a 13-modality CDMO landscape, both SCTbio and Takeda qualify as Cell Therapy manufacturers; Takeda carries the higher composite Signal Score for Cell Therapy programs in this comparison.
What to evaluate for Cell Therapy programs
Both SCTbio and Takeda qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Frequently asked: SCTbio vs Takeda
How does SCTbio compare to Takeda for Cell Therapy manufacturing?
On CDMO Signal's composite Signal Score, SCTbio is 82/100 and Takeda is 82/100; SCTbio has 0 FDA inspections on record vs 4 for Takeda; European coverage is 5 active EMA+MHRA certificates for SCTbio vs 18 for Takeda. Both are tracked in the CDMO Signal directory as Cell Therapy CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, SCTbio or Takeda?
Both SCTbio and Takeda maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. SCTbio has 0 FDA inspections on record; Takeda has 4.
How do SCTbio and Takeda compare on European GMP coverage?
SCTbio holds 5 active EMA GMP certificates and 0 MHRA / UK certificates. Takeda holds 18 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — SCTbio or Takeda?
SCTbio is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Takeda is matched to 100. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Cell Therapy manufacturing — SCTbio or Takeda?
Both SCTbio and Takeda are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →